New Drugs for HDL-C Disorders: The Beginning
Stephen J. Nicholls.
For more than 20 years there has been increasing interest in the development of novel therapies to raise levels
of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that
raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic
target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality.
These will be reviewed.
Keywords: Atherosclerosis, cardiovascular disease, HDL, lipids, risk factors.
Rights & PermissionsPrintExport